{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:38:17Z","timestamp":1792712297543,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Dutch Cancer Society","doi-asserted-by":"publisher","award":["13651"],"award-info":[{"award-number":["13651"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","award":["PPP grant"],"award-info":[{"award-number":["PPP grant"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021821","name":"Oncode Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021821","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["ZonMw VIDI"],"award-info":[{"award-number":["ZonMw VIDI"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.trecan.2026.09.008","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:01:58Z","timestamp":1792616518000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancing functional treatment prediction for precision oncology"],"prefix":"10.1016","author":[{"given":"Eveline C.","family":"Smit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia M.","family":"Komar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedwig M.","family":"Blommestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk M.W.","family":"Verheul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1522-3496","authenticated-orcid":false,"given":"Daniele V.F.","family":"Tauriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dik C.","family":"van Gent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.09.008_bb0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.trecan.2026.09.008_bb0010","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1158\/1078-0432.CCR-24-2820","article-title":"AACR cancer progress report 2024: inspiring science\u2014fueling progress\u2014revolutionizing care","volume":"30","author":"Williams","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.008_bb0015","series-title":"Comparator Report on Cancer in Europe 2025 \u2013 Disease Burden, Costs and Access to Medicines and Molecular Diagnostics. IHE REPORT 2025:2","author":"Manzano","year":"2025"},{"key":"10.1016\/j.trecan.2026.09.008_bb0020","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.09.008_bb0025","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ddr.21029","article-title":"Companion diagnostics and the drug-diagnostic codevelopment model","volume":"73","author":"J\u00f8rgensen","year":"2012","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.trecan.2026.09.008_bb0030","article-title":"Imatinib: a breakthrough of targeted therapy in cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Res. Pract."},{"key":"10.1016\/j.trecan.2026.09.008_bb0035","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.09.008_bb0040","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.2016.311","article-title":"PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: current practice and future directions","volume":"115","author":"Konecny","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2026.09.008_bb0045","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","article-title":"Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis","volume":"2","author":"Schwaederle","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2026.09.008_bb0050","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1158\/1078-0432.CCR-21-3752","article-title":"Patients with rare cancers in the drug rediscovery protocol (DRUP) benefit from genomics-guided treatment","volume":"28","author":"Hoes","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.008_bb0055","doi-asserted-by":"crossref","first-page":"482","DOI":"10.21037\/atm.2016.12.26","article-title":"Companion diagnostics\u2014a tool to improve pharmacotherapy","volume":"4","author":"J\u00f8rgensen","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.trecan.2026.09.008_bb0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41568-022-00529-3","article-title":"The coming decade in precision oncology: six riddles","volume":"23","author":"Wahida","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2026.09.008_bb0065","doi-asserted-by":"crossref","DOI":"10.4155\/fsoa-2017-0003","article-title":"Ex vivo tumor culture systems for functional drug testing and therapy response prediction","volume":"3","author":"Meijer","year":"2017","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.trecan.2026.09.008_bb0070","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.3390\/cells11223705","article-title":"In vitro veritas: from 2D cultures to organ-on-a-chip models to study immunogenic cell death in the tumor microenvironment","volume":"11","author":"Krysko","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.trecan.2026.09.008_bb0075","doi-asserted-by":"crossref","first-page":"0022","DOI":"10.34133\/bmef.0022","article-title":"Organotypic models for functional drug testing of human cancers","volume":"4","author":"Huang","year":"2023","journal-title":"BME Front."},{"key":"10.1016\/j.trecan.2026.09.008_bb0080","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/bit.26845","article-title":"3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs","volume":"116","author":"Nunes","year":"2019","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.trecan.2026.09.008_bb0085","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1073\/pnas.1015938108","article-title":"Retaining cell\u2013cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer","volume":"108","author":"Kondo","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2026.09.008_bb0090","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1158\/2159-8290.CD-17-0833","article-title":"Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids","volume":"8","author":"Jenkins","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.09.008_bb0095","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","article-title":"Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology","volume":"56","author":"Thorel","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.trecan.2026.09.008_bb0100","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.09.008_bb0105","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.3390\/cancers15143677","article-title":"Validation of a novel EUS-FNB-derived organoid co-culture system for drug screening in patients with pancreatic cancer","volume":"15","author":"Gr\u00fctzmeier","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.09.008_bb0110","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jcmgh.2020.09.003","article-title":"Cancer-associated fibroblasts provide a stromal niche for liver cancer organoids that confers trophic effects and therapy resistance","volume":"11","author":"Liu","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.trecan.2026.09.008_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1105244","article-title":"Dendritic cell phenotype and function in a 3D co-culture model of patient-derived metastatic colorectal cancer organoids","volume":"14","author":"Subtil","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.09.008_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350891","article-title":"cDC2 plasticity and acquisition of a DC3-like phenotype mediated by IL-6 and PGE2 in a patient-derived colorectal cancer organoids model","volume":"54","author":"Subtil","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.trecan.2026.09.008_bb0125","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/0008-5472.CAN-20-1674","article-title":"Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high-grade serous ovarian cancer","volume":"81","author":"Wan","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.008_bb0130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/0022034520956614","article-title":"3D co-culture of cancer-associated fibroblast with oral cancer organoids","volume":"100","author":"Zhao","year":"2021","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.trecan.2026.09.008_bb0135","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.09.008_bb0140","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","article-title":"An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer","volume":"27","author":"Voabil","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.09.008_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101221","article-title":"Motion based ex vivo (MOTEX) culture of breast tumor slices sustains microenvironment composition","volume":"68","author":"Komar","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.trecan.2026.09.008_bb0150","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41576-022-00466-9","article-title":"Human organs-on-chips for disease modelling, drug development and personalized medicine","volume":"23","author":"Ingber","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.trecan.2026.09.008_bb0155","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.trecan.2026.09.008_bb0160","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1073\/pnas.0401064101","article-title":"Reconstruction of functionally normal and malignant human breast tissues in mice","volume":"101","author":"Kuperwasser","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2026.09.008_bb0165","series-title":"Focus Group Organ-on-Chip Standardization Roadmap","author":"Focus Group Organ-on-Chip","year":"2024"},{"key":"10.1016\/j.trecan.2026.09.008_bb0170","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41523-023-00583-6","article-title":"Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients","volume":"9","author":"Ladan","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.trecan.2026.09.008_bb0175","article-title":"A 3D pancreatic cancer model with integrated optical sensors for noninvasive metabolism monitoring and drug screening","volume":"13","author":"Siciliano","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.trecan.2026.09.008_bb0180","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3390\/cancers14051252","article-title":"Functional ex vivo tissue-based chemotherapy sensitivity testing for breast cancer","volume":"14","author":"Ladan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.09.008_bb0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41523-025-00734-x","article-title":"Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay","volume":"11","author":"Komar","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.trecan.2026.09.008_bb0190","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3390\/cells12050807","article-title":"Perfusion air culture of precision-cut tumor slices: an ex vivo system to evaluate individual drug response under controlled culture conditions","volume":"12","author":"Dong","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.trecan.2026.09.008_bb0195","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41568-022-00517-7","article-title":"Tumour avatars to model patients\u2019 responses to immunotherapy","volume":"22","author":"Thommen","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2026.09.008_bb0200","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13046-024-02980-6","article-title":"Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response","volume":"43","author":"Smabers","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.008_bb0205","article-title":"Unified framework for patient-derived, tumor-organoid-based predictive testing of standard-of-care therapies in metastatic colorectal cancer","volume":"4","author":"Tan","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2026.09.008_bb0210","article-title":"Patient-derived organoids from colorectal cancer with paired liver metastasis reveal tumor heterogeneity and predict response to chemotherapy","volume":"9","author":"Mo","year":"2022","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.trecan.2026.09.008_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-63170-0","article-title":"An optimised patient-derived explant platform for breast cancer reflects clinical responses to chemotherapy and antibody-directed therapy","volume":"14","author":"Demetriou","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2026.09.008_bb0220","doi-asserted-by":"crossref","first-page":"811","DOI":"10.18632\/oncotarget.28508","article-title":"Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma","volume":"14","author":"Kim","year":"2023","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2026.09.008_bb0225","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/0008-5472.CAN-16-1121","article-title":"Ex vivo explant cultures of non-small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy","volume":"77","author":"Karekla","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.008_bb0230","article-title":"A clinical evaluation of an ex vivo organ culture system to predict patient response to cancer therapy","volume":"10","author":"Golan","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.trecan.2026.09.008_bb0235","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12967-016-0861-5","article-title":"Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer","volume":"14","author":"Owonikoko","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.trecan.2026.09.008_bb0240","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","article-title":"Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors","volume":"28","author":"Izumchenko","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.09.008_bb0245","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.09.008_bb0250","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-15-2936","article-title":"Ex vivo testing of patient-derived xenografts mirrors the clinical outcome of patients with pancreatic ductal adenocarcinoma","volume":"22","author":"Roife","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.008_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107116","article-title":"Cutoff value of IC50 for drug sensitivity in patient-derived tumor organoids in colorectal cancer","volume":"26","author":"Tang","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.trecan.2026.09.008_bb0260","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jtho.2021.01.1616","article-title":"Biomarker discovery and validation: statistical considerations","volume":"16","author":"Ou","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2026.09.008_bb0265","series-title":"Regulation (EU) 2017\/746 of the European Parliament and of the Council of 5 April 2017 on In Vitro Diagnostic Medical Devices and Repealing Directive 98\/79\/EC and Commission Decision 2010\/227\/EU","author":"European Parliament and Council","year":"2017"},{"key":"10.1016\/j.trecan.2026.09.008_bb0270","series-title":"In Vitro Companion Diagnostic Devices: Guidance for Industry and Food and Drug Administration Staff","author":"FDA","year":"2014"},{"key":"10.1016\/j.trecan.2026.09.008_bb0275","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1158\/1078-0432.CCR-23-4026","article-title":"A phase III randomized trial of integrated genomics and avatar models for personalized treatment of pancreatic cancer: the AVATAR Trial","volume":"31","author":"Sarno","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.008_bb0280","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13046-023-02683-4","article-title":"Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study","volume":"42","author":"Jensen","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.008_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100103","article-title":"Prospective experimental treatment of colorectal cancer patients based on organoid drug responses","volume":"6","author":"Ooft","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.trecan.2026.09.008_bb0290","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1186\/s12885-023-11362-8","article-title":"The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer","volume":"23","author":"Divoux","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trecan.2026.09.008_bb0295","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12894-023-01262-1","article-title":"Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial","volume":"23","author":"Seiler","year":"2023","journal-title":"BMC Urol."},{"key":"10.1016\/j.trecan.2026.09.008_bb0300","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12885-025-13590-6","article-title":"The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors","volume":"25","author":"Gall","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trecan.2026.09.008_bb0305","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1158\/1538-7445.AM2024-5174","article-title":"Abstract 5174: organoids to predict treatment response in metastatic colorectal cancer (OPTIC)","volume":"84","author":"Smabers","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.09.008_bb0310","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2022.09.005","article-title":"Access and quality of biomarker testing for precision oncology in Europe","volume":"176","author":"Normanno","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2026.09.008_bb0315","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1186\/s12885-021-08725-4","article-title":"How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review","volume":"21","author":"Seo","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trecan.2026.09.008_bb0320","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1186\/s12885-019-6270-4","article-title":"Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer","volume":"19","author":"Martin","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trecan.2026.09.008_bb0325","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/jpm12071025","article-title":"Stakeholders perceptions of barriers to precision medicine adoption in the United States","volume":"12","author":"Schroll","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.trecan.2026.09.008_bb0330","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/14737159.2020.1757436","article-title":"Challenges in the clinical implementation of precision medicine companion diagnostics","volume":"20","author":"Keeling","year":"2020","journal-title":"Expert. Rev. Mol. Diagn."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326002190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326002190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:48:20Z","timestamp":1792709300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326002190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":66,"alternative-id":["S2405803326002190"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.09.008","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing functional treatment prediction for precision oncology","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}